Stock Events

Stock Events

Outlook Therapeutics 

€0.2
0
+€0.01+5.23% Friday 19:47

Statistics

Day High
0.2
Day Low
0.19
52W High
2.47
52W Low
0.17
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q4 2025
Next
-0.19
-0.16
-0.13
-0.1
Expected EPS
-0.1033312176
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 41O.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals competes in the ophthalmology space, particularly with treatments for eye diseases, directly competing with Outlook Therapeutics' eye therapy products.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO Inc. focuses on the development of gene therapy products for eye diseases, offering direct competition to Outlook Therapeutics' gene therapy approaches for ocular diseases.
Novartis
NVS
Mkt Cap297.32B
Novartis AG has a strong presence in the ophthalmology market, including therapies for macular degeneration and other eye conditions, competing with Outlook Therapeutics.
Bausch Health Companies
BHC
Mkt Cap1.99B
Bausch Health Companies Inc., through its eye health division, provides a wide range of products for eye conditions, directly competing with Outlook Therapeutics.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie, after acquiring Allergan, has become a significant player in the eye care market, offering products that compete with Outlook Therapeutics' treatments.
Rogers
ROG
Mkt Cap1.88B
Roche Holding AG, with its ophthalmology division, offers treatments for various eye diseases, competing with Outlook Therapeutics in the broader eye care market.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. has investments in treatments for eye diseases, including therapies for retinal disorders, making it a competitor to Outlook Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division, develops treatments for eye health, including surgery and vision care, competing with Outlook Therapeutics.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline plc, with its healthcare portfolio, includes treatments for eye conditions, indirectly competing with Outlook Therapeutics in the healthcare market.

About

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Show more...
CEO
Mr. Robert Charles Jahr
Employees
17
Country
Germany
ISIN
US69012T3059

Listings

STU
DE
41O.STU
MU
DE
41O.MU
F
DE
41O.F
XNAS
US
OTLK

0 Comments

Share your thoughts

FAQ

What is Outlook Therapeutics stock price today?▼
The current price of 41O.STU is €0.2 EUR — it has increased by +5.23% in the past 24 hours. Watch Outlook Therapeutics stock price performance more closely on the chart.
What is Outlook Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Outlook Therapeutics stocks are traded under the ticker 41O.STU.
Is Outlook Therapeutics stock price growing?▼
41O.STU stock has risen by +8.35% compared to the previous week, the month change is a -45.25% fall, over the last year Outlook Therapeutics has showed a -82.49% decrease.
When is the next Outlook Therapeutics earnings date?▼
Outlook Therapeutics is going to release the next earnings report on May 14, 2026.
What were Outlook Therapeutics earnings last quarter?▼
41O.STU earnings for the last quarter are -0.19 EUR per share, whereas the estimation was -0.19 EUR resulting in a +2.94% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Outlook Therapeutics have?▼
As of April 12, 2026, the company has 17 employees.
In which sector is Outlook Therapeutics located?▼
Outlook Therapeutics operates in the Other sector.
When did Outlook Therapeutics complete a stock split?▼
Outlook Therapeutics has not had any recent stock splits.
Where is Outlook Therapeutics headquartered?▼
Outlook Therapeutics is headquartered in Iselin, Germany.